+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying the effects of prasinezumab, given as an intravenous infusion, in people aged 50 to 85 with early-stage Parkinsons disease who are already receiving stable levodopa treatment. The study aims to compare prasinezumab to a placebo to evaluate its safety, how the body processes the drug, and its impact on motor symptoms related to Parkinsons disease. Participants will be randomly assigned to receive either prasinezumab or a placebo through IV infusions during the double-blind treatment phase. After this phase, eligible participants can join an open-label extension where they receive prasinezumab. The study follows participants for at least 104 weeks, with infusions and assessments scheduled throughout this period. During the study, participants will have regular visits for motor function assessments using the Movement Disorder Society Unified Parkinsons Disease Rating Scale MDS-UPDRS and other measures. Researchers will monitor adverse events, infusion reactions, and the presence of antibodies against prasinezumab. Blood samples will be taken at multiple time points to measure drug levels and immune responses. The total study duration extends through 2031, including safety follow-up after the last dose.

Age: 50Years - 85YearsAll GendersPhase 3
192 locations
E

Actively Recruiting

Researchers are evaluating the effects of a robotic rehabilitation treatment using a bilateral exoskeleton called Bilateral Robot-Assisted Therapy BRAT compared to conventional arm rehabilitation. The study focuses on people who have had a stroke in the subacute phase, aiming to understand how BRAT impacts motor recovery of the upper limb. The main goal is to determine if BRAT improves motor function better than standard rehabilitation, measured by the Fugl-Meyer Assessment for the upper limb. Participants are randomly assigned to two groups. The experimental group receives standard rehabilitation plus a daily 45-minute BRAT session using the Arm Light Exoskeleton Hybrid Alex RS - Wearable Robotics. They complete around 16 treatment sessions over four weeks, with personalized exercises and progressive difficulty. The control group receives conventional upper limb rehabilitation for 45 minutes daily, also totaling about 16 sessions over four weeks, focusing on motor exercises led by a therapist without robotic devices. Participants are evaluated with clinical exams and rating scales at baseline, after treatment, and three months later by telephone follow-up. Assessments include motor function, muscle tone, cognitive abilities, hand dexterity, satisfaction, and daily activity performance. The study also uses neurophysiological and biomechanical measures to analyze motor recovery. The total study duration includes enrollment, treatment, and data analysis phases over 24 months.

Age: 18Years +All GendersPhase Not Applicable
3 locations
L

Actively Recruiting

Researchers are conducting a long-term observational study called MARKERS-NDD to collect data from patients with various neurodegenerative diseases. These diseases, including Parkinsons Disease, dementia, and related disorders, currently lack therapies that change their course. The study aims to improve early diagnosis and prediction of disease progression by analyzing clinical markers and using artificial intelligence to identify new diagnostic and prognostic indicators. Participants in MARKERS-NDD will be followed over 1 to 10 years during routine clinical visits. The study collects data from clinical evaluations, movement and gait analysis using motion capture and wearable sensors, brain imaging, neuropsychological and voice assessments, electroencephalography, and laboratory tests. AI-driven systems will analyze handwriting and voice patterns to detect motor and cognitive changes, supporting remote diagnosis and telemonitoring. Throughout participation, patients will undergo various assessments during normal care visits, including movement analysis, cognitive testing, brain imaging, and blood tests. Researchers will monitor and predict disease progression using these clinical markers along with AI models over up to 10 years. The study aims to develop tools to better understand neurodegenerative diseases and support their management through non-invasive, cost-effective methods.

Age: 10Years +All Genders
1 location
E

Actively Recruiting

Researchers are studying how different amounts of aerobic exercise affect brain-derived neurotrophic factor BDNF levels in people with Parkinsons disease. This observational pilot study will enroll 30 participants and compare two exercise groups to understand how exercise volume influences changes in BDNF and other biomarkers, motor and non-motor symptoms, cognitive function, and brain connectivity. Participants will be assigned to either an Extensive Rehabilitation Group doing low-intensity aerobic exercise twice a week with a total exercise volume of 180 METs-minutes per week, or an Intensive Rehabilitation Group performing high-intensity aerobic exercise five days a week totaling 1350 METs-minutes per week. Both groups will follow their assigned exercise programs for four weeks. During the study, participants will undergo assessments of blood biomarkers including BDNF and others at 4, 8, and 12 weeks. Researchers will also evaluate motor symptoms, gait analysis, cognitive tests, quality of life, depressive symptoms, and brain activity using EEG and fMRI. This comprehensive evaluation aims to capture the effects of exercise on Parkinsons disease over the 12-week observation period.

Age: 30Years - 80YearsAll Genders
1 location